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ABSTRACT 
In Medicinal chemistry, heterocyclic derivatives contributed 
the largest classical division of organic chemistry. Thiadiazole 
compounds have been known for many biological activities such 
as hypoglycemic, anticancer, anti-inflammatory, anti-asthmatic, 
antihypertensive etc. On this research, several 1,1-bis [2-{2-(5-
(arylidene)imino-1,3,4-thiadiazol-2-yl) methyl amino}- 1,3,4-
thiadiazo-5-yl] cyclopropane 5(a-h) have been synthesized from 
cyclopropane dicarboxylic acid comprising thiadiazole moieties. All 
the synthesized compounds have been characterized by 
elemental (C,H,N) and spectral (I.R., 1H- NMR, Mass) analysis. 
Furthermore, all synthesized compounds were screened for their 
antifungal, antimicrobial, anti-inflammatory, analgesic, ulcerogenic 
and toxic activities. The Compound 5f, 3-chlorophenyl substituted 
was found the most potent in antimicrobial spectrum against all 
the used microbes. On the other hand, compound 5g, 4-hydroxy-
3-methoxy phenyl substituted was found the most potent in anti-
inflammatory, analgesic, and ulcerogenic activities which further 
evaluated for lesser toxicity test. 
 
Key words: bis-phenylarylidinylthiadiazolidinone cyclopropane, anti-
microbial, anti-inflammatory, analgesic, ulcerogenic and toxicity studies.  
 
INTRODUCTION 
Currently using non-steroidal anti-
inflammatory drugs (NSAIDs) viz. ibuprofen, 
diclofenac, indomethacin and flurbiprofen 
cause gastric toxicity. Their prolong use 
resulted into gastro-intestinal (GI) ulceration, 
bleeding and nephrotoxicity (Kimmey 1992). 
On the other hand, there is no 
chemotherapeutic agent which is found to 
show anti-inflammatory as well as known 
antibacterial activities. In medicinal chemistry, 
heterocyclic derivatives contributed the largest 
classical division of organic chemistry. Organic 
chemistry is providing facile and efficient 
methodology for the synthesis of different 
heterocyclic moieties due to their versatile 
biological spectrum. Microbial infections cause 
pain and inflammation. In the current study, we 
have focused on thiadiazoles due to its versatile 
biological profile such as hypoglycemic 
(Avetisyan et al., 1981), anticancer (Parkanyi et 
al. 1992), anti-inflammatory (Boschelli et al., 
1993; Labanauskas et al., 2001; Schenone et al., 
2001), anti-asthmatic (Bhattacharya et al., 2005), 
antihypertensive (Vio et al., 1989), 
antidepressant (Clerici et al., 2001), anxiolytic 
(Clerici et al., 2001), fungicidal (Chen and Hen, 
2000; Zou et al., 2002; Zou et al., 2002) and anti-
tuberculosis (Foroumadi et al., 2001). On the 
other hand, esters of 1,1-cyclopropane 
dicarboxylic acid were found to possess 
important insecticidal activity (Ronald and 
Leland 1998). Furthermore bulk of literature is 
available to explore the biological importance 
of Schiff bases (Ibrahim et al., 2011; Sah et al., 
2011; Sanjeeva et al., 2010) especially 
antimicrobial and thus aroused our interest in 
the synthesis of some novel bis Schiff bases. 
Based on the wide spectrum of biological 
profile of 1,1-propane dicarboxylic acid, 
thiadiazole, Schiff base and their importance in 
pharmaceutical, biological field and in 
continuation of our ongoing research on 
biologically active heterocycles (Panwar et al., 
2006; Goel et al., 2004; Kumar et al., 2003; 
Panwar et al., 2011; Panwar et al., 2011), it was 
thought of interest to accommodate 1,1-
propane dicarboxylic acid, thiadiazole and aryl 
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aldehydes in a single molecular frame work of 
designing to synthesize some novel bis 
heterocycles for enhancing biological activity 
with lesser toxicity. 
 
MATERIAL AND METHODS 
All the chemicals used for the 
preparation of desired derivatives, were 
obtained from Sisco Research Laboratories 
(SRL), Mumbai, India; Qualigen Fine 
Chemicals, Mumbai, India; E. Merck Ltd., New 
Delhi, India. Reference drugs ampicillin 
trihydrate and fluconazole were procured from 
Ind-Swift Pharmaceutical, Panjab, India and 
Macleods Pharmaceutical, Mumbai, India 
respectively. The melting points of the 
compounds were determined in open glass 
capillaries with the help of thermonic melting 
points apparatus (Campbell Electronics, 
Mumbai, India) and are uncorrected. The 
homogenity of all the newly synthesized 
compounds were routinely checked by TLC on 
silica gel G plates and spots were located by 
using iodine chamber. Elemental analysis was 
performed in Heraeus C H N rapid analyser. 
The results were found within the ±0.4% of 
theoretical values. Infrared spectra were 
recorded on KBr pellets on a Perkin Elmer 
system 2000 FTIR spectrometer and 1H- NMR 
spectra on Bruker DPX 200 using TMS as 
internal standard.  
 
Anti-inflammatory activity 
Anti-inflammatory activity was 
determined against carrageenan induced rat’s 
paw edema (Winter et al., 1962). The rats were 
divided into three groups (control, drug treated, 
and standard, each groups contain 6 animals). A 
freshly prepared suspension of carrageenan 
(1% in 0.9% saline). 0.05mL was injected under 
the planter aponeurosis of the right hind paw 
of each rat. Test compounds and standard drug 
were administered orally to the animals of drug 
treated groups and the standard drug group, 
respectively, 1 h before the carrageenan 
injection. The paw volume of each rat was 
measured before 1 and after 3h of carrageenan 
treatment with the help of a plethymometer. 
The percent anti-inflammatory activity was 
calculated according to the formula given 
below: 
  
Percentage of inhibition 
of edema 
: 
1 – Vt 
X 100 
Vc 
 
Where, Vt and Vc are the mean increase 
in paw volume of rats of the treated and the 
control group, respectively. Results obtained 
were statistically analyzed. 
 
Analgesic activity 
Analgesic activity was performed 
following the method of Berkowitz et al., 1977.  
This method is based on the property of the 
test compound to antagonize the 
phenylquinone-induced pain syndrome in mice. 
Groups of five mice were injected 
intraperitonealy with 0.25mL of a 0.02% 
solution of phenylquinone in ethanol (5%) 1h 
after oral administration of the test compound. 
The number of writhes induced in each mouse 
was counted for 5min (between 5 and 10min) 
after injection of an irritant. The analgesic 
effect was expressed as percent protection in 
comparison to control.  
% protection = (1 - mean no. of writhes in 
mice of test groups/ mean number of writhes 
in mice of control group) X 100 
 
Ulcerogenic activity 
Ulcerogenic labilities of newly 
synthesized compounds were checked (Verma 
et al., 1981) in albino mices. Albino rats were 
fasted for 24 h prior to drug administration. All 
animals were sacrificed 8 h after drug 
treatment, and their stomachs and small 
intestines were microscopically examined to 
assess the incidence of hyperemia, shedding of 
epithelium, petechial and frank hemorrhages 
and erosion or discrete ulceration with or 
without perforation. The presence of any one 
of these criteria was considered to be an 
evidence of ulcerogenic activity. 
 
COX-1 and COX-2 activities 
The compounds prepared were tested 
for cyclooxygenase-1 and cyclooxygenase-2 
inhibitory activities (Copeland et al., 1994) 
followed to determine the IC50 values. The 
enzyme activity is measured using chromogenic 
assay based on oxidation of N, N, N’, N’-
tetramethyl-p-phenylenediamine (TMPD) 
during the reduction of prostaglandin G2 to 
prostaglandin H2 by COX-1 and COX-2 
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enzymes. COX-1 and COX-2 enzymes used in 
the assay were purified from microsomal 
fraction. The compounds were dissolved in 
DMSO and stock solution was diluted to 
required assay concentration. The assay mixture 
consists of Tris-HCl. Tris-HCl buffer (pH 8.0, 
100μM). hematin (15μM), EDTA (3mm), 
enzyme (COX-1 or COX-2, 100μM) and test 
compound. The mixture was pre-incubated at 
25°C for 15min and then the reaction was 
initiated by the addition of arachidonic acid 
(100μM) and TMPD (120μM) in total volume 
of 1.0mL. The enzyme activity was measured 
by estimating the initial velocity of TMPD 
oxidation for the first 25s of the reaction 
following the increase in absorbance at 603nm. 
IC50 values are calculated from four parameter 
least squares non-linear regression analysis of 
the log dose vs percentage inhibition plot. 
However, none of the compound studied here 
exhibited significant inhibitory activity when 
compared to standard inhibitors indomethacin 
(for COX-1) and celecoxib (for COX-2). 
 
Antimicrobial screening 
All the newly synthesized compounds 
were screened for their antibacterial and 
antifungal activity. All the bacterial and fungal 
strains were clinical isolates, identified with 
conventional morphological and biochemical 
methods. Bacterial inhibition diameter was 
measured in mm.  Microorganisms employed 
antibacterial studies were Staphylococcus aureus, 
Escherichia coli, Klabsiella pneumoniae and Proteus 
vulgaris. Disk diffusion method (Cruickshank et 
al., 1975; Collins 1976) was used for 
determination of the preliminary antibacterial 
activity. Sterile 5mm Whatman no. 1 filter 
paper discs were used in the disc diffusion 
method. Batches of 100 disks were dispensed 
to each screw-capped bottle and sterilized by 
dry heat at 140°C for 1h. The test compounds 
were prepared with different concentrations 
using DMF. One hundred milliliters of the 
microbial suspension was spread onto nutrient 
agar plates. Disks of each concentration were 
for placed in triplicate in nutrient agar medium 
seeded with fresh bacteria separately. The 
incubation was carried out at 37°C for 24h. 
Ampicillin trihydrate was used as a standard 
drug. Solvent and growth controls were kept 
and zones of inhibition were noted (Table I). 
On the other hand, the newly prepared 
compounds were screened for their in vitro 
antifungal activity against Aspergillus fumigatus 
(plant isolate), Candida glabrata, Candida albacans 
and Candida krusei in DMSO by the serial plate 
dilution method (Khan, 1997; Varma, 1998). 
Fluconazole (antifungal) was used as reference 
drug. Sabouraud’s agar media were prepared by 
dissolving peptone (1g), D-glucose (4g), and 
agar (2g) in distilled water (100mL) and 
adjusting the pH to 5.7. Normal saline was used 
to make a suspension of the spore of fungal 
strain for lawning. A loopful of particular 
fungal strain was transferred to 3 ml saline to 
get a suspension of the corresponding species. 
Agar media (20mL) was poured into each petri 
dish. Excess suspension was decanted and the 
plates were dried by placing in an incubator at 
37°C for 1h. Using an agar punch wells were 
made into each well labeled. A control was also 
prepared in triplicate and maintained at 37°C 
for 3-4 days. Antifungal activity was determined 
by measuring the diameter of the inhibition 
zone in mm (Table I).  
 
Acute toxicity test 
Lethal dose (LD50) (Carrol 1952) of test 
compounds were determined in albino mice. 
After 24h of drug administration, percent 
mortality in each group was observed from the 
data obtained LD50. Data revealed that 
compound 5f does not show any toxicity up to 
dose of 9.95mg/mL body weight in mice. 
 
Synthesis of 1,1-bis (2-amino-1,3,4-
thiadiazol-5-yl) cyclopropane (1) 
A mixture of 1,1-cyclopropane 
dicarboxylic acid (0.01mol), thiosemicarbazide 
(0.02mol) and phosphorous oxychloride (5mL) 
was gently refluxed for 30min. After cooling, 
water (10mL) was added and the reaction 
mixture was refluxed for four hours and 
filtered. The completion of reaction of reaction 
was checked by TLC. The cooled, refluxed 
residue was poured into ice-water slowly with 
continuous stirring, the solution was 
neutralized with aqueous 3% KOH solution 
and the precipitate was filtered and recrystallized 
by methanol: Yield: 67%; m.p.: 235-238°C; Rf: 
0.50; IR (KBr, cm–1): 3280 (NH2), 1605 (C=N), 
665 (C-S-C); 1H-NMR (CDCl3, δ/ ppm):  6.40 
(s, 4 H, 2 X 2H, NH2), 1.18-1.00 (m, 4H, 2 X 
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2H, CH2); MS (m/z, %): 240.31. Anal. calcd. for 
C7H8N6S2: C, 34.99; H, 3.36; N, 34.97%. 
Found: C, 35.00; H, 3.35; N, 34.98%. 
 
Synthesis of 1,1-bis (2-Carboethoxy-
methylamino-1,3,4-thiadiazol-5-yl) 
cyclopropane (2) 
A mixture of compound 1 and 
chloroethylacetate (0.01mol) in dry dioxane (50 
ml) was refluxed for 8h. The reaction mixture 
was further stirred for 1h, and poured in water. 
The resulting mixture was filtered and 
recrystallized from ethanol to yield compound 
2: Yield: 54%; m.p.:  209°C; Rf : 0.61;  IR (KBr, 
cm–1): 3185(N-H), 2950 (C-H aliphatic), 
1695(C=O), 1603 (C=N), 1295(N-N), 1242(C-
N), 670 (C-S-C); 1H-NMR (CDCl3, δ / ppm): 
6.02 (t, 2H, 2X1H, NH, exchangeable with 
D2O), 4.55 (d, 4H, 2X 2H, NH-CH2), 4.12(q, 
4H, 2 X 2H, 2H-COOCH2-CH3), 1.45 (t, 6H, 
2X3H, COOCH2-CH3), 1.20-1.05 (m, 4H, 2 X 
2H, CH2); MS (m/z, %): 412.49. Anal. calcd. for 
C15H20N6S2O4: C, 43.68; H, 4.89; N, 20.37 %. 
Found: C, 43.66; H, 4.87; N, 20.43 %. 
 
Synthesis of 1, 1-bis [2-{(2-Thiosemi-
carbazido)carbonylmethylamino}- 1,3,4 
-thiadiazo-5-yl] cyclopropane (3) 
The equimolar mixture (0.02mol) of 
compound 2 and thiosemicarbazide (0.02mol) 
in methanol (50mL) was refluxed for 10h. The 
excess of solvent was distilled off and viscous 
mass was poured into water, dried and 
recrystallized from methanol to yield 
compound 3. 
Yield: 56 %; m.p.: 181 °C; Rf : 0.63; IR 
(KBr, cm–1): 3189(N-H), 2956 (C-H aliphatic), 
1692 (C=O), 1606 (C=N), 1298(N-N), 1240(C-
N), 677 (C-S-C); 1H-NMR (CDCl3, δ / ppm): 
8.12-7.48 (m, 8H, 2 X 4H, NHNHCSNH2, 
exchangeable with D2O), 6.12(t, 2H, 2X 1H, 
NH, exchangeable with D2O), 4.47(d, 4H, 2 X 
2H, NH-CH2), 1.08-0.96(m, 4H, 2 X 2H,CH2); 
MS (m/z, %): 502.62. Anal. calcd. for 
C13H18N12O2S4 : C, 31.06; H, 3.61; N,33.44 %. 
Found: C, 31.12; H, 3.65; N, 33.50 %. 
 
Synthesis of 1, 1-bis [2-{2-(5-amino            
-1,3,4-thiadiazol-2-yl) methylamino}- 
1,3,4-thiadiazo-5-yl] cyclopropane (4) 
A mixture of compound 3 (0.01mol) and 
conc. H2SO4 (20mL) was kept overnight at 
room temperature, poured into ice-cold water, 
neutralized with liquid ammonia and filtered. 
The product thus obtained was recrystallized 
from ethanol water to furnish compound 4. 
Yield: 56%; m.p.: 279°C; Rf :0.67; IR (KBr, cm–
1): 3190(N-H), 2952 (C-H aliphatic), 1689 
(C=O), 1609 (C=N), 1288 (N-N), 1238(C-N), 
671 (C-S-C); 1H-NMR (CDCl3, δ / ppm): 
6.26(bs, 4H, 2 X 2H, NH2), 5.75(s, 2H, 2 X 1H, 
NH, exchangeable with D2O), 4.47(d, 4H, 2 X 
2H, NH-CH2), 1.08-0.96(m, 4H, 2 X 2H,CH2); 
MS (m/z, %): 466.59. Anal. calcd. for 
C13H14N12S4: C, 33.46; H, 3.02; N,36.02 %. 
Found: C, 33.41; H, 3.02; N, 36.30 %. 
 
General procedure for the Synthesis of 
1, 1-bis [2-{2-(5-(arylidene)imino-1,3, 
4-thiadiazol-2-yl) methyl amino}-1,3, 
4-thiadiazo-5-yl] cyclopropane 5(a-h) 
A mixture of compound 4 (0.01mol) and 
proper aromatic aldehydes (0.01mol) in 
methanol (50mL) was refluxed for 5-7h, in the 
presence of few drops of glacial acetic acid. The 
progress and completion of reaction was 
checked by TLC. The reaction mixtures were 
distilled off cooled and then poured into ice 
water, filtered, washed with water and dried to 
get compounds 5(a-h). The crude solids thus 
obtained were recrystallized from appropriate 
solvents.  
5a.Yield: 51%; m.p.: 228 °C; Rf : 0.59;  
IR (KBr, cm–1): 3020 (C-H-Ar), 2942 (C-H 
aliphatic), 1690(C=O), 1598 (C=N), 1292(N-
N), 1246(C-N), 680 (C-S-C);1H-NMR (CDCl3, 
δ / ppm): 8.38 (s, 2H, 2X 1H, N=CH-Ph),7.60-
6.66 (m, 10H, 2 X Ph), 6.38(brs, 2H, 2 X 1H, 
NH), 5.62 (s, 2H, 2 X 1H, NH, exchangeable 
with D2O), 4.63(d, 2H,NH-CH2),1.01-0.90(m, 
4H, 2X 2H, CH2); MS (m/z, %): 642.80. Anal. 
calcd. for C27H22N12S4 : C,50.45; H,3.45; 
26.15%. Found: C, 50.50; H, 3.57; N, 26.21%. 
5b. Yield: 49%; m.p.: 290 °C; Rf : 0.68;  IR 
(KBr, cm–1): 3016 (C-H-Ar), 2946 (C-H), 
1700(C=O), 1604 (C=N), 791(C-Cl), 676(C-S-
C); 1H-NMR (CDCl3, δ / ppm): 8.42 (s, 2H, 2X 
1H, N=CH-Ph),7.76-6.67 (m, 8H, 2 X Ph), 
6.31(brs, 2H, 2 X 1H, NH), 5.60 (s, 2H, 2 X 
1H, NH, exchangeable with D2O), 4.60(d, 
2H,NH-CH2),1.11-0.97(m, 4H, 2X 2H, CH2); 
MS (m/z, %): 711.69. Anal. calcd. for 
C27H20N12S4Cl2 : C,45.57; H,2.83; 23.62%. 
Found: C, 45.54; H, 2.85; N, 23.64%. 5c. Yield: 
52%; m.p.: 166 °C; Rf : 0.62;  IR (KBr, cm–1): 
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3021 (C-H-Ar), 2944 (C-H), 1706(C=O), 1627 
(C-C of aromatic ring),1607 (C=N), 672(C-S-
C); 1H-NMR (CDCl3, δ / ppm): 8.46 (s, 2H, 2X 
1H, N=CH-Ph), 7.85-6.64 (m, 8H, 2 X Ph), 
6.22 (brs, 2H, 2 X 1H, NH, exchangeable with 
D2O), 4.56(d, 4H, 2 X 2H, NH-CH2), 2.41 (s, 
6H, 2X 3H,H3C-Ph), 1.16-1.04(m, 4H, 2X 2H, 
CH2); MS (m/z, %): 670.86. Anal. calcd. for 
C29H26N12S4 : C,51.92; H,3.91; 25.05%. Found: 
C, 51.89; H, 3.92; N, 25.09%. 5d. Yield: 46%; 
m.p.: 237 °C; Rf : 0.68;  IR (KBr, cm–1): 3025 
(C-H-Ar), 2947 (C-H), 1704 (C=O), 1628 (C-C 
of aromatic ring), 1604 (C=N), 790(C-Cl), 
677(C-S-C); 1H-NMR (CDCl3, δ / ppm): 8.40(s, 
2H, 2X 1H, N=CH-Ph), 7.83-6.69 (m, 8H, 2 X 
Ph), 6.25 (brs, 2H, 2 X 1H, NH exchangeable 
with D2O), 4.65(d, 2H, NH-CH2), 2.44 (s, 6H, 
2X 3H,H3C-Ph),1.14-1.00(m, 4H, 2X 2H, 
CH2); MS (m/z, %): 711.69. Anal. calcd. for 
C27H20N12S4Cl2 : C,45.57; H,2.83; 23.62%. 
Found: C, 45.53; H, 2.80; N, 23.59%. 5e. Yield: 
52%; m.p.: 249°C; Rf : 0.62;  IR (KBr, cm–1): 
3018 (C-H-Ar), 2939 (C-H), 1698(C=O), 1618 
(C-C of aromatic ring), 1610 (C=N), 668(C-S-
C); 1H-NMR (CDCl3, δ / ppm): 8.35 (s, 2H, 2X 
1H, N=CH-Ph), 7.83-6.69 (m, 8H, 2 X Ph), 
6.25 (brs, 2H, 2 X 1H, NH, exchangeable with 
D2O), 4.65(d, 4H, 2 X 2H, NH-CH2), 2.39 (s, 
6H, 2X 3H,H3C-Ph), 1.18-1.05(m, 4H, 2X 2H, 
CH2); MS (m/z, %): 670.86. Anal. calcd. for 
C29H26N12S4 : C,51.92; H,3.91; 25.05%. Found: 
C, 51.90; H, 3.90; N, 25.15%. 5f. Yield: 44%; 
m.p.: 265°C; Rf : 0.63; IR (KBr, cm–1): 3020 (C-
H-Ar), 2942 (C-H), 1697(C=O), 1622 (C-C of 
aromatic ring), 1600 (C=N), 787(C-Cl), 671(C-
S-C); 1H-NMR (CDCl3, δ / ppm): 8.37 (s, 2H, 
2X 1H, N=CH-Ph),7.78-6.72 (m, 8H, 2 X Ph), 
6.31(brs, 2H, 2 X 1H, NH), 5.60 (s, 2H, 2 X 
1H, NH, exchangeable with D2O), 4.60(d, 
2H,NH-CH2),1.11-0.97(m, 4H, 2X 2H, CH2); 
MS (m/z, %): 711.69. Anal. calcd. for 
C27H20N12S4Cl2 : C,45.57; H,2.83; 23.62%. 
Found: C, 45.52; H, 2.81; N, 23.60%. 5g. Yield: 
47%; m.p.: 133 0C; Rf : 0.66;  IR (KBr, cm–1): 
3016 (C-H-Ar), 2947 (C-H), 1701(C=O), 1620 
(C-C of aromatic ring), 1605 (C=N), 670(C-S-
C); 1H-NMR (CDCl3, δ / ppm): 10.45 (s, 2H, 
2X1H, HO-Ph), 8.30 (s, 2H, 2X 1H, N=CH-
Ph), 7.80-6.69 (m, 8H, 2 X Ph), 6.26 (brs, 2H, 2  
X 1H,  NH,  exchangeable  with D2O),  4.56(d,  
 
4H, 2 X 2H, NH-CH2), 2.39 (s, 6H, 2X 
3H,H3C-Ph), 1.18-1.06(m, 4H, 2X 2H, CH2); 
MS (m/z, %): 674.80. Anal. calcd. for 
C27H22N12S4O2 : C,48.06; H, 3.29; 24.91%. 
Found: C, 51.90; H, 3.90; N, 25.15%. 5h. Yield: 
50%; m.p.: 216°C; Rf : 0.63;  IR (KBr, cm–1): 
3022 (C-H-Ar), 2945 (C-H), 1710(C=O), 1625 
(C-C of aromatic ring), 1610 (C=N), 1165(C-
O-C), 679(C-S-C); 1H-NMR (CDCl3, δ / ppm): 
10.45 (s, 2H, 2X1H, HO-Ph), 8.30 (s, 2H, 2X 
1H, N=CH-Ph), 7.80-6.69 (m, 8H, 2 X Ph), 
6.26 (brs, 2H, 2 X 1H, NH, exchangeable with 
D2O), 4.56(d, 4H, 2 X 2H, NH-CH2), 2.39 (s, 
6H, 2X 3H,H3C-Ph), 1.18-1.06(m, 4H, 2X 2H, 
CH2); MS (m/z, %): 734.85. Anal. calcd. for 
C29H26N12S4O2 : C,47.40; H, 3.57; 22.87%. 
Found: C, 47.45; H, 3.60; N, 22.85%. 
 
RESULTS AND DISCUSSION 
Chemistry 
1,1-Cyclopropane dicarboxylic acid  
prepared according to the method in the 
literature (Singh and Danishefsky, 1990). 1,1-
Cyclopropane dicarboxylic acid  was refluxed 
with thiosemicarbazide and phosphorous 
oxychloride to furnish1,1-bis(2-amino-1,3,4-
thiadiazol-5-yl) cyclopropane (1) in good yield. 
Reaction of compound (1) with chloroethyl-
acetate in dry dioxane afforded 1,1-bis (2-
carboethoxymethylamino-1,3,4-thiadiazol-5-yl) 
cyclopropane (2) which on further reaction 
with thosemicarbazide yielded 1,1-bis [2-{(2-
thiosemicarbazido) carbonylmethylamino}- 1,3, 
4-thiadiazo-5-yl] cyclopropane (3). Compound 
(3) in presence of concentrate sulphuric acid, 
cyclised to give 1,1-bis [2-{2-(5-amino -1, 3, 4-
thiadiazol-2-yl) methylamino}- 1,3,4-thiadiazo-
5-yl]cyclo propane (4). The synthesis of target 
derivatives, schiff bases i.e. 1, 1-bis [2-{2-(5-
(arylidene)imino- 1,3,4-thiadiazol-2-yl) methyl 
amino}- 1,3,4-thiadiazo-5-yl] cyclopropane 5(a-
h) were afforded by the reaction of different 
aromatic aldehydes with compound (4) in 
presence of glacial acetic acid (Figure 1). 
 
Pharmacology 
Compounds 4, 5a-f wrere evaluated for 
antimicrobial, anti-inflammatory, analgesic and 
ulcerogenic activities. The biological evaluation 
data   were   summarized   in   table  I  and II.  
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Synthetically derived molecules 4, 5a-f were 
assayed by using the disk diffusion method and 
serial plate method for antimicrobial activity 
against selected pathogenic clinical strains. The 
screening results were compared with standard 
ampicillin trihydrate and fluconazole 
respectively  for   antibacterial   and   antifungal  
testing respectively. From the antimicrobial 
screening data of compounds 4 and 5a-h, it was 
found that conversion of thiadiazole derivative 
i.e. 4 into Schiff bases i.e. 5a-h, brought 
enhancing antibacterial and antifungal activity. 
Compound 5f claimed the most remarkable 
antimicrobial spectrum against all the used 
microbes. It showed more potency against K. 
pneumoniae, P. vulgaris and comparable against S. 
aureus with standard drug ampicillin trihydrate 
while on the other hand, remaining tested 
compounds exhibited mild to moderate activity. 
Among the derivatives 5(a-h), derivative 5b, 5c 
and 5d showed moderate potency while 
compounds 5a, 5e, 5g and 5h showed poor 
antimicrobial activity against the used 
pathogenic strains.  
Anti-inflammatory, analgesic and 
ulcerogenic activities of all the compounds 4, 
5(a-h) showed significant results. The 
Compound 4 displayed poor activity data than 
the compounds 5a-h. All the compounds 5a-h 
has shown promising degree (32.60-42.00%) of 
anti-inflammatory activity in comparison to 
phenylbutazone. Derivatives 5b, 5d and 5f 
bearing 2-chlorophenyl, 4-chlorophenyl and 3-
chlorophenyl substitution showed similar 
inhibition of edema. Results revealed that 
compounds 5a, 5b, 5c, 5d, 5e, 5f and 5h 
showed 32.78%, 36.00%, 35.70%, 35.97%, 
32.60%, 36.25% and 34.10% inhibition of 
edema. Compound 5g that was 4-hydroxy-3-
methoxy phenyl substituted, has shown the 
maximum percentage of anti-inflammatory 
activity, i.e. 42.00% at a dose of 50 mg/kg/ p.o. 
Considering, the potentiality of compounds 5g, 
it was studied in detail at three graded doses 25, 
50, 100 mg/kg/ p.o. and exhibited better anti-
inflammatory activity as compared to 
phenylbutazone. The ulcerogenic liability of 
compound   5g   (132.10mg/kg/i.p.)   is   much          
Table I. Antimicrobial data for the synthesized compounds 4 and 5(a-h). 
 
    
 
 
Antibacterial inhibition (mm) Antifungal inhibition (mm) 
Comp. no. 
S. 
aureus 
E. 
Coli 
K. 
pneumoniae 
P. 
vulgaris 
A. 
fumigatus 
C. 
glabrata 
C. 
albacans 
C. 
krusei 
4. - - 5 8 - - 5 - 
5a. - 5 5 8 5 - - - 
5b. 12 8 6 12 10 8 10 10 
5c. 8       7 8 15 14 5 5 - 
5d. 14 15 12 15 6 10 8 12 
5e. 6 - 10 8 10 - - 6 
5f. 15 20 26 22 15 10 12 13 
5g. 6 - 8 8 - 6 - 5 
5h. 6 10 10 6 - 8 - - 
Ampicillin 
trihydrate 
(std.) 
16 20 20 20 - - - - 
Fluconazole 
(std.) 
- - - - 20 15 16 15 
DMF 
(control) 
- - - - - - - - 
 
-: showing no activity 
 
 
 
Ravindra Kumar 
Volume 26 Issue 1 (2015) 7 
less than that of indomethacin (55.56mg/kg/ 
i.p.) and phenylbutazone (66.21mg/kg/i.p.).              
The most active compound of this series            
was 5g which has shown potent analgesic 
activity, i.e. 42.00% at a dose of 50mg/kg/         
p.o. Moreover, at three (25, 50 and 100)        
graded doses, compound 5g displayed             
better analgesic activity than phenylbutazone, 
while  it  was   less   active  then  indomethacin.  
All these compounds were also evaluated for 
COX-1 and COX-2 inhibitory activities. 
Compound 5g exhibited 68.40% and 92.20% 
Table IIa. Antimicrobial data for the synthesized compounds 4 and 5(a-h). 
 
     
 
 
Comp. No. R Anti inflammatory activity Analgesic activity 
  
Dose 
(mg/kg /p.o.) 
% inhibition 
of edema 
Dose 
(mg/kg/p.o.) 
% 
Protection 
Phenylbutazone  25 
50 
100 
26.60*** 
37.20*** 
64.50** 
25 
50 
100 
14.25*** 
32.55*** 
54.58*** 
Indomethacin  5.0 
7.5 
10.0 
52.50*** 
63.00*** 
92.40*** 
5.0 
7.5 
10.0 
42.30*** 
59.25*** 
65.30*** 
4.  50 31.15*** 50 21.10** 
5a. H 50 32.78*** 50 20.90** 
5b. 2-Cl 50 36.00*** 50 35.10*** 
5c. 4-CH3 50 35.70*** 50 21.20** 
5d. 4-Cl 50 35.97*** 50 19.90** 
5e. 2-CH3 50 32.60*** 50 22.60*** 
5f. 3-Cl 50 36.25*** 50 18.75** 
5g. 4-OH 25 
50 
100 
28.70*** 
42.00*** 
66.75*** 
25 
50 
100 
19.00*** 
38.00*** 
58.00*** 
5h. 4-OH,  
3-OCH3 
 34.10*** 50 19.95** 
 
 
Table IIb. Antimicrobial data for the synthesized compounds 4 and 5(a-h). 
 
UD50 (mg/kg/i.p.) IC50 % of inhibition ALD50 (mg/kg/i.p.) 
 COX-1 COX-2 >800 
66.21 - - >800 
55.56 - - >800 
- 37.45*** 76.56*** >800 
- 38.15*** 72.42*** >800 
- 38.70*** 64.33*** >800 
- 39.55*** 66.17*** >800 
- 39.25** 71.23*** >800 
- 37.10** 65.80*** >800 
- 37.45** 63.56*** >800 
132.10 68.40** 92.20*** >800 
- 39.25** 70.40*** >800 
 
*P< 0.05, **P<0.01, ***P<0.001, - denotes not tested; Propylene glycol standard for control group. 
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inhibition of action. Moreover, rest of the 
compounds  showed  moderate  degree of  COX-1 
and COX-2 inhibitory actions suggesting that 
these compounds showed anti-inhibitory 
activity by inhibition of both COX-1 and 
COX-2 enzymes. ALD50 of all these 
compounds were >800 mg/kg/ i.o. (Table-II). 
 
CONCLUSION 
Antimicrobial evaluation of compound 4 
and 1,1-bis (2-phenyl-5-arylidine-1,3-
thiadiazolidin-4-one) cyclopropanes (5a-h) 
revealed that conversion of compound 4 into 
Schiff bases (5a-h) enhances biological potency 
viz. antimicrobial, anti-inflammatory, analgesic 
and ulcerogenic activities. Compound 5f 
possessing 3-chlorophenyl substitution; 
displayed the most potent antimicrobial 
spectrum as well as anti-inflammatory and 
analgesic activity. On the other hand, 
compound 5g, 4-hydroxy-3-methoxy phenyl 
substituted was found the most potent in anti-
inflammatory, analgesic, and ulcerogenic 
activities and deserves further investigation in 
order to clarify the mode of action at molecular 
level, responsible for the activity observed. 
    
 
 
 
 
R = C6H5, 2-ClC6H4, 4-CH3C6H4, 4-ClC6H4, 2-CH3C6H4, 3-ClC6H4, 4-OHC6H4, 3-OCH3(4-OH)C6H3 
 
Figure 1. The synthesis of target derivatives, schiff bases i.e. 1, 1-Bis [2-{2-(5-(arylidene)imino- 
1,3,4-thiadiazol-2-yl) methyl amino}- 1,3,4-thiadiazo-5-yl] cyclopropane 5(a-h) were afforded by 
the reaction of different aromatic aldehydes with compound (4) in presence of glacial acetic acid. 
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